arrow
H

Halvard Bönig

Goethe University
H指数:52
被引数:9,094

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
Leukemia
IF13.4
2026-08-310
OA
Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium

更正:学术生产CAR-T细胞质量控制测试的协调:UNITC联盟WP-bioproduction工作组立场文件

2025-06-300
OAAI
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+rhabdomyosarcoma

Car-cik与car-t: 将新型细胞因子诱导的杀伤细胞作为ErbB2横纹肌肉瘤实体瘤免疫疗法的基准

2025-02-030
OAAI
MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中,通过用HER2-TARGETED嵌合抗原受体工程化的自然杀伤细胞局部治疗与全身ANTI-PD-1检查点抑制相结合来调节肿瘤内免疫微环境

2024-11-110
PRE
A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中重复颅内注射单独使用HER2-TARGETED嵌合抗原受体并结合全身ANTI-PD-1检查点抑制的自然杀伤细胞

2024-10-170
PRE
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease (vol 21, 837, 2023)
2024-06-130
OAAI